Haemonetics (HAE) Capital Expenditures (2009 - 2026)

Haemonetics' Capital Expenditures history runs 18 years deep, the most recent figure standing at $17.7 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 12.9% year-over-year to $17.7 million in Q1 2026; TTM through Mar 2026 was $32.8 million, a 16.54% decrease from a year earlier, with the FY2026 full-year figure at $32.8 million, down 16.54% from the prior year.
• Capital Expenditures advanced to $17.7 million in Q1 2026 per HAE's latest filing, from $6.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $93.1 million in Q2 2023 and bottomed at $3.8 million in Q2 2025.
• The 5-year median for Capital Expenditures is $12.0 million (2023), against an average of $20.2 million.
• Across the five-year window, Capital Expenditures soared 226.65% in 2022 and plunged 92.82% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $16.8 million in 2022, then dropped by 13.07% to $14.6 million in 2023, then tumbled by 41.65% to $8.5 million in 2024, then retreated by 25.71% to $6.3 million in 2025, then surged by 178.17% to $17.7 million in 2026.
• Per Business Quant, the three latest HAE Capital Expenditures figures stand at $17.7 million (Q1 2026), $6.3 million (Q4 2025), and $5.0 million (Q3 2025).